{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.8","value":"68.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.9","value":"74.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"title":"Day 28"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.2","value":"79.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"title":"Month 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.6","value":"81.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"title":"Month 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.1","value":"81.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"title":"Month 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.0","value":"86.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"title":"Month 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.6","value":"87.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"title":"Month 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.9","value":"93.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Month 18"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.9","value":"97.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Month 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"description":"EQ-5D is a self-reported questionnaire used for assessing the overall health status of a participant. The EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single index value. The EQ-5D-VAS records the participant's self-rated health on a 20-cm vertical visual analogue scale and is asked to make a global assessment of their current state of health with 0 indicating the worst health they can imagine and 100 indicating the best health they can imagine. Higher scores indicated a better health state.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with r/r B-ALL received conditioning chemotherapy (fludarabine 25 mg/m\\^2 IV over 30 minutes on Day -4, Day -3, and Day -2 and cyclophosphamide 900 mg/m\\^2 IV over 60 minutes on Day -2) followed by a single infusion of brexucabtagene autoleucel CAR transduced autologous T cells administered IV at a target dose of 1 x 10\\^6 anti-CD19 CAR T cells/kg of body weight on Day 0. For participants weighing \\> 100 kg, a maximum flat dose of 1 x 10\\^8 anti-CD19 CAR T cells/kg of body weight was administered.","id":"OG000","title":"Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg"}],"paramType":"MEAN","populationDescription":"Participants in Safety Analysis Set with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 28, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, and Month 24","title":"Phase 2: EQ-5D Visual Analogue Scale (VAS) Score","type":"SECONDARY","unitOfMeasure":"score on a scale"}